Recipharm AB has entered into a strategic collaboration with Alcon, a Novartis company, and a long-term supply agreement to manufacture a range of ophthalmic products using Blow Fill Seal technology. Additionally, Recipharm will acquire Alcon’s Kaysersberg Pharmaceuticals for €18 million, gaining its manufacturing facility in Kaysersberg, France, which currently supplies this product range.
 
The long term manufacturing agreement is expected to add annual sales of more than €36 million and extends Recipharm’s manufacturing services offering with Blow Fill Seal technology. Approximately 260 Kaysersberg employees will continue their roles under Recipharm.
 
Thomas Eldered, chief executive officer Recipharm AB said, “We are looking forward to extending our relationship with Alcon and Novartis and I am very pleased that they have had the confidence in Recipharm to make this commitment of a long term manufacturing agreement and sale of Kaysersberg Pharmaceuticals. Blow Fill Seal technology is a very interesting area, which we believe will grow and it therefore forms an important addition to our portfolio. The high skill levels and dedicated employees in Kaysersberg will be a welcome addition into Recipharm and we look forward to working with them to further develop and grow the business.”